此乃要件 請即處理 閣下對本通函任何內容如有疑問，應諮詢 閣下的股票經紀或其他註冊證券交易商、銀行 經理、律師、專業會計師或其他專業顧問。 閣下如已出售或轉讓名下所有麗珠醫藥集團股份有限公司的股份，應立即將本通函交予買 方或受讓人或經手出售的銀行、股票經紀或其他代理商，以便轉交買方或受讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部份內容而產 生或因倚賴該等內容而致的任何損失承擔任何責任。 麗 珠 醫 藥 集 團 股 份 有 限 公 司 LIVZON PHARMACEUTICAL GROUP INC.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：1513） (I)向關連附屬公司提供持續擔保 獨立董事委員會及獨立股東之獨立財務顧問 (II)建議募集資金投資項目結項並將節餘募集資金永久補充流動資金 (III)建議選舉非執行董事 及 (IV)臨時股東大會通知 董事會函件載於本通函第6至21頁。獨立董事委員會函件載於本通函第22至23頁，當中載有 其就202 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 特別決議案 1. 審議及批准本公司與控股附屬公司麗珠單抗訂立的2025年-2027年三年持續擔保支持 框架協議，及其項下擬進行的本公司為麗珠單抗提供融資擔保的持續關連交易以及 年度擔保上限。 普通決議案 附註： 1. 根據香港聯合交易所有限公司證券上市規則（「上市規則」），臨時股東大會上所有決議案將以投票方 式進行表決。投票結果將按照上市規則規定刊載於香港交易及結算所有限公司的網站(www. hkexnews.hk)及本公司的網站(www.livzon.com.cn)。 — 1 — 麗 珠 醫 藥 集 團 股 份 有 限 公 司 LIVZON PHARMACEUTICAL GROUP INC.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：1513） 二零二四年第三次臨時股東大會通知 茲通告麗珠醫藥集團股份有限公司Livzon Pharmaceutic ...

Financial Performance - Total revenue for Q3 2024 was ¥2,799,249,537.14, a decrease of 5.59% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2024 was ¥501,763,106.12, an increase of 7.45% year-over-year[3] - Net profit excluding non-recurring gains and losses for Q3 2024 was ¥475,333,392.49, a decrease of 1.36% compared to the same period last year[3] - Basic earnings per share for Q3 2024 was ¥0.54, an increase of 8.00% year-over-year[3] - The company's operating revenue for the first nine months of 2024 was RMB 9,081.60 million, a decrease of 5.94% compared to RMB 9,654.79 million in the same period of 2023[8] - The net profit attributable to shareholders of the parent company for the first nine months of 2024 was RMB 1,672,733,989.63, an increase of 4.44% from RMB 1,601,554,878.96 in the previous year[19] - The company's operating profit for the first nine months of 2024 was RMB 2,315,421,100.65, up 16.49% from RMB 1,987,239,809.53 in the same period of 2023[19] - The total comprehensive income for the first nine months of 2024 was RMB 1,896,000,641.95, an increase from RMB 1,548,036,443.08 in the same period of 2023[20] Assets and Liabilities - Total assets as of the end of Q3 2024 were ¥24,909,308,152.30, a decrease of 0.54% from the end of the previous year[4] - The company's total liabilities increased by 147.35% to RMB 1,631.71 million from RMB 659.68 million, primarily due to the transfer of long-term borrowings due within one year[8] - The total liabilities as of the end of the reporting period were RMB 9,973,518,408.08, a decrease from RMB 10,278,124,131.71 at the beginning of the year[18] - The total current assets decreased from RMB 17,266,174,718.28 at the beginning of the year to RMB 16,613,394,001.59[17] - The non-current assets increased from RMB 7,778,652,409.47 at the beginning of the year to RMB 8,295,914,150.71[17] Shareholder Information - Shareholders' equity attributable to the parent company was ¥14,158,595,462.73, an increase of 0.83% from the end of the previous year[4] - The company reported a total of 926,904,495 shares outstanding as of the latest disclosure date[4] - The total number of ordinary shareholders at the end of the reporting period was 41,320, with the top ten shareholders holding significant stakes, including Hong Kong Central Clearing Limited at 33.11%[10] - The company repurchased a total of 7,855,000 A shares, representing 0.85% of the total share capital, with a total expenditure of RMB 276,508,263.84[13] - The company also repurchased 4,763,400 H shares, with the remaining shares accounting for 0.21% of the total share capital, and a total expenditure of HKD 116,981,345.00[14] Cash Flow - Cash flow from operating activities for the period from January to September 2024 was ¥2,307,915,362.28, an increase of 4.32% year-over-year[3] - The total cash inflow from operating activities for the first nine months of 2024 was CNY 10,217,108,238.70, a decrease of 5.2% compared to CNY 10,775,261,897.57 in the same period of 2023[21] - The net cash flow from operating activities increased to CNY 2,307,915,362.28, up by 4.3% from CNY 2,212,403,355.39 year-on-year[21] - Cash inflow from financing activities increased to CNY 3,166,957,767.39, up 14.3% from CNY 2,770,410,168.70 year-on-year[21] - The ending balance of cash and cash equivalents was CNY 10,723,355,139.50, an increase from CNY 9,995,849,149.30 in the same period last year[21] Financial Ratios and Metrics - The weighted average return on equity for Q3 2024 was 3.56%, an increase of 0.13 percentage points compared to the previous year[3] - The financial expenses decreased by 74.63% to RMB -54.93 million from RMB -216.48 million year-on-year, mainly due to reduced interest income from deposits and foreign exchange losses[8] - The company's financial expenses showed a significant improvement, with a net financial expense of -RMB 54,930,249.12 compared to -RMB 216,475,683.51 in the previous year[19] - Research and development expenses for the first nine months of 2024 amounted to RMB 734,493,897.75, a decrease of 25.49% compared to RMB 985,755,413.94 in the previous year[19] Other Information - Government subsidies recognized in Q3 2024 amounted to ¥32,137,493.67, contributing positively to the financial results[5] - The company did not undergo an audit for the third quarter report[22] - The report indicates that the company has adopted new accounting standards starting from 2024[22]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而刊發。 茲載列麗珠醫藥集團股份有限公司於深圳證券交易所網站刊發之《麗珠醫藥集團股份有 限公司第十一屆董事會第二十次會議決議公告》，僅供參閱。 承董事會命 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc. * 公司秘書 楊亮 中國，珠海 二零二四年十月二十三日 於本公告日期，本公司的執行董事為唐陽剛先生 ( 總裁 ) 及徐國祥先生 ( 副董事長及副總裁 ); 本 公司的非執行董事為朱保國先生 ( 董事長 ) 、陶德勝先生 ( 副董事長 ) 及邱慶豐先生 ; 而本公司 的獨立非執行董事為白華先生、田秋生先生、黃錦華先生、羅會遠先生及崔麗婕女士。 * 僅供識別 1 证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2024-063 丽珠医药集团股份有限公司 第十 ...

Financial Performance - The total revenue for the first half of 2024 was RMB 6,282.35 million, representing a decrease of 6.09% compared to the same period in 2023[17]. - The net profit attributable to shareholders was RMB 1,170.97 million, down 3.21% year-over-year[17]. - The cash flow from operating activities was RMB 1,155.47 million, reflecting a decrease of 5.65% compared to the previous year[17]. - The basic earnings per share increased to RMB 1.27, up 4.10% from RMB 1.22 in the same period last year[18]. - The overall revenue from raw materials and intermediates was RMB 745.01 million, reflecting a decrease of 11.86%[20]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2024, representing a 15% year-over-year growth[33]. - The company reported a revenue of RMB 6,282.35 million for the first half of 2024, a decrease of 6.09% compared to RMB 6,689.92 million in the same period last year[46]. - Net profit attributable to shareholders was RMB 1,170.97 million, reflecting a growth of 3.21% from RMB 1,134.57 million year-on-year[46]. - The net profit excluding non-recurring gains and losses was RMB 1,155.47 million, an increase of 5.65% from RMB 1,093.71 million in the previous year[47]. - The net cash flow from operating activities increased by 24.67% to RMB 1,530.03 million, compared to RMB 1,227.31 million in the previous period[40]. Revenue Breakdown - The revenue from chemical preparations accounted for 28.03% of total revenue, amounting to RMB 1,761.08 million[20]. - The revenue from biological products decreased by 61.23%, totaling RMB 70.52 million[21]. - The company’s revenue from traditional Chinese medicine preparations increased by 32.33%, reaching RMB 394.35 million[21]. - Sales revenue from chemical preparations was RMB 3,223.84 million, a decline of 7.37%, accounting for 51.32% of the total revenue[49]. - The sales revenue of the biopharmaceutical segment was RMB 87.55 million, a year-on-year decrease of 22.80%, accounting for 1.39% of the total revenue[55]. - The sales revenue of raw materials and intermediates segment reached RMB 1,761.08 million, a year-on-year decrease of 1.16%, accounting for 28.03% of the total revenue[58]. - The sales revenue of traditional Chinese medicine preparations was RMB 745.01 million, down 21.89% year-on-year, representing 11.86% of total revenue[62]. - The sales revenue of diagnostic reagents and equipment increased by 32.33% year-on-year to RMB 394.35 million, making up 6.28% of total revenue[64]. Future Outlook and Strategies - The company has provided a positive outlook for the second half of 2024, projecting a revenue growth of 10% to 12%[33]. - New product development includes the launch of a novel drug expected to enter the market by Q4 2024, which is anticipated to generate an additional 300 million RMB in revenue[33]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[33]. - A strategic acquisition of a local pharmaceutical company is in progress, which is expected to enhance the company's production capacity by 30%[33]. - The company plans to enhance its digital marketing strategies, aiming for a 15% increase in online sales by the end of 2024[33]. - The company is focusing on core areas such as gastrointestinal, neuropsychiatric, reproductive assistance, metabolism, and anti-infection for its chemical preparations segment in the second half of 2024[53]. Research and Development - The company has invested 100 million RMB in R&D for innovative drug formulations in the first half of 2024, a 50% increase from the previous year[33]. - The company has made significant progress in key projects, including the approval of the 8 mg hydrochloride paliperidone tablets and the submission of supplementary materials for the injection of triptorelin microspheres for endometriosis[50]. - The company is advancing the development of key biopharmaceutical projects, including the completion of patient enrollment for the phase III clinical trial of recombinant human follicle-stimulating hormone injection[55]. - The company is actively expanding its international business, with the injection of acetic acid cyproterone approved for sale in the United States and ongoing sales and registration efforts in multiple countries[51]. - The company has established a modular and flat R&D management system, enhancing project management and resource allocation for competitive innovation projects[50]. - The company is focusing on evidence-based marketing and compliance marketing to promote its core products effectively[51]. Investment and Financial Management - The company has received emergency use approval for its bivalent COVID-19 vaccine, which has been shipped to multiple provinces for vaccination[56]. - The company aims to accelerate the commercialization process of its biopharmaceutical products while enhancing its quality management system[57]. - The company has a rolling bill pool business limit of RMB 1.8 billion, with a pledged balance of RMB 296,090,600[104]. - The company has received production approval for several new products, including the injection of aripiprazole microspheres for schizophrenia, which is expected to enhance its product offerings[81]. - The company has made significant equity investment of RMB 1,000,000,000 in Zhuhai Lizhu Biological, holding a 60.23% stake[133]. - The company reported a loss from the investment in Zhuhai Lizhu Biological of RMB -106,335,367.68[134]. - The company has established a management system for commodity futures hedging to mitigate market risks associated with commodity price fluctuations[142]. Share Repurchase and Capital Management - The company approved a share repurchase plan for A-shares with a total fund amount between RMB 400 million and RMB 600 million, with a maximum repurchase price of RMB 38.00 per A-share[199]. - As of June 30, 2024, the company repurchased a total of 2,152,600 A-shares, accounting for 0.23% of the total issued share capital and 0.35% of the total issued A-shares, with a total expenditure of RMB 73,436,534.00[199]. - In July 2024, the company repurchased an additional 2,741,600 A-shares, representing 0.30% of the total issued share capital and 0.44% of the total issued A-shares, with a total expenditure of RMB 98,431,542.00[200]. - The repurchased A-shares have not yet been canceled and will reduce the registered capital upon cancellation[200]. - The company aims to stabilize its development and protect shareholder interests through this repurchase initiative[199].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 麗 珠 醫 藥 集 團 股 份 有 限 公 司 LIVZON PHARMACEUTICAL GROUP INC.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：1513） 截至2024年6月30日止六個月的未經審計中期業績公告 麗珠醫藥集團股份有限公司Livzon Pharmaceutical Group Inc.*（「本公司」，連同其附屬公 司統稱為「本集團」）董事會（「董事會」）謹此宣佈本集團截至2024年6月30日止六個月的未 經審計中期業績。本業績公告列載本公司2024年中期報告全文，並符合《香港聯合交易所 有限公司證券上市規則》中有關中期業績初步公告附載的資料之要求。 本業績公告的中英文版本可在本公司網站(www.livzon.com.cn)和香港交易及結算所有限公 司（「香港交易所」）網站(www.hkexnews.hk)查閱。 2024年中期報告將於適當時候於香港交易所網站(w ...

Financial Performance - Livzon Pharmaceutical Group reported a revenue of RMB 1.2 billion for the first half of 2024, representing a 15% increase compared to the same period in 2023[1]. - The company's net profit for the first half of 2024 was RMB 300 million, up 20% year-over-year[1]. - Livzon Pharmaceutical has projected a revenue growth of 12% for the full year 2024, aiming for a total revenue of RMB 2.5 billion[1]. - The company reported a fully diluted earnings per share of RMB 1.26[16]. - The company reported a revenue of RMB 6,282.35 million for the current period, a decrease of 6.09% compared to RMB 6,689.92 million in the previous period[21]. - Net profit attributable to shareholders was RMB 1,170.97 million, reflecting a growth of 3.21% from RMB 1,134.57 million in the prior period[21]. - The net profit excluding non-recurring gains and losses was RMB 1,155.47 million, up 5.65% from RMB 1,093.71 million year-on-year[21]. - The net cash flow from operating activities increased by 24.67% to RMB 1,530.03 million compared to RMB 1,227.31 million in the previous period[21]. - Basic and diluted earnings per share were both RMB 1.27, representing a 4.10% increase from RMB 1.22 in the previous period[21]. - The weighted average return on equity rose to 8.04%, an increase of 0.15 percentage points from 7.89%[21]. Market Expansion and Strategy - User data indicates a growth in the customer base by 10% in the first half of 2024, reaching 1.5 million active users[1]. - Livzon plans to expand its market presence in Southeast Asia, targeting a 5% market share by the end of 2025[1]. - The company is actively pursuing market expansion strategies to enhance its competitive position[10]. - The company has established a strong presence in both domestic and international markets, leveraging its diverse product portfolio[10]. - The company is focusing on enhancing its operational management and R&D efficiency while advancing its digital transformation efforts[21]. Research and Development - The company is investing RMB 200 million in R&D for new drug development, focusing on oncology and autoimmune diseases[1]. - Livzon has launched two new products in the first half of 2024, contributing to a 30% increase in sales from new product lines[1]. - The company maintains its commitment to research and development, focusing on new product innovations and technologies[10]. - The group is focusing on the development of innovative pipelines in key areas such as digestive, neurological, reproductive, metabolic, and anti-infection fields for the second half of 2024[23]. - The group plans to accelerate the market launch of innovative drugs, including the injectable Aripiprazole microspheres, and enhance compliance marketing strategies[23]. - The company has made significant progress in its R&D projects, with several key products receiving approval or progressing through clinical trials[22]. Financial Management and Investments - The company has not declared any cash dividends for the current fiscal year, focusing on reinvestment for growth[1]. - The company has not made any retrospective adjustments or restatements of previous years' accounting data[14]. - The company continues to monitor and adapt to regulatory changes in the pharmaceutical industry to ensure compliance and operational efficiency[10]. - The company has established a comprehensive quality management system that ensures the safety and stability of its products, enhancing market competitiveness[37]. - The company has implemented a foreign exchange risk management policy to mitigate the impact of currency fluctuations on its operations[68]. - The company has not made any significant acquisitions or other major investments during the reporting period[73]. Regulatory Compliance and Governance - The company continues to comply with both international accounting standards and Chinese accounting standards without discrepancies in net profit and net assets[15]. - The company emphasizes quality control and compliance with Good Manufacturing Practices (GMP) in its operations[9]. - The company has confirmed compliance with the Hong Kong Listing Rules and the Corporate Governance Code from January 1, 2024, to June 30, 2024[193]. - The company has established an ESG Committee to promote and implement ESG initiatives within the group[195]. - The company has maintained effective management decision-making and supervision processes in accordance with regulatory requirements[194]. - The Audit Committee is responsible for reviewing the financial reports and risk management systems, ensuring the integrity of financial reporting[196]. Employee and Shareholder Engagement - The total employee compensation for the reporting period was RMB 948.24 million, an increase of 10.3% from RMB 859.95 million in the previous period[71]. - The group employed 8,920 employees as of June 30, 2024, slightly down from 8,933 employees at the end of 2023[71]. - The average duration of the top five customers as clients is 16.60 years, indicating strong customer loyalty[42]. - The average duration of the top five suppliers as partners is 13.60 years, reflecting stable supplier relationships[42]. - The company has established a management committee elected by the holders' meeting to oversee the daily management of the third phase plan[183]. Stock Options and Incentive Plans - The 2022 stock option incentive plan involves granting 20 million stock options, with 18 million options (90%) allocated for initial grants and 2 million options (10%) reserved[112]. - The company has established a performance assessment mechanism where individual performance affects the exercise ratio of stock options, with a maximum of 100% for excellent performance[125]. - The company will cancel stock options that do not meet the performance assessment targets for the corresponding year[124]. - The company plans to adjust the investment plan for the Aprazole project due to unmet funding progress expectations in 2020[111]. - The total number of shares held under the third phase of the employee stock ownership plan shall not exceed 10% of the company's total share capital, with individual employee holdings capped at 1%[181].

Financial Performance - In 2023, Livzon Pharmaceutical Group achieved a revenue of RMB 12,430.04 million, a year-on-year decrease of 1.58%[8] - The net profit attributable to shareholders was RMB 1,953.65 million, reflecting a year-on-year growth of 2.32%[8] - The company reported a total operating revenue of RMB 12,430.04 million, reflecting a decrease of 1.58% compared to the previous year[15] - The net profit attributable to shareholders was RMB 1,953.65 million, with a decrease of 2.32% year-on-year[15] - The company reported a significant decline of 79.33% in revenue from traditional Chinese medicine products, totaling RMB 84.43 million[19] - The company achieved a 17.18% increase in cash flow from operating activities, amounting to RMB 2,382.67 million[16] - The company reported a total cash flow from operating activities of RMB 1.04 billion in Q4 2023, showing a positive trend in cash generation[39] - The company’s net profit from core business, excluding non-recurring items, was RMB 1,881.35 million, a slight increase of 0.05% year-on-year[48] - The company reported a significant increase of 6,218.19% in current non-current liabilities, primarily due to the reclassification of long-term borrowings[100] Dividend Distribution - The company plans to distribute a cash dividend of RMB 13.50 per 10 shares, pending approval at the annual general meeting[8] - The dividend distribution is based on the total share capital as of the record date, excluding repurchased but not canceled shares[20] - The expected payment dates for the cash dividends are July 8, 2024, for A-share shareholders and August 5, 2024, for H-share shareholders[20] Research and Development - The company has made significant progress in its R&D innovation system, focusing on differentiated product pipelines in areas such as oncology and reproductive health[9] - The company plans to focus on enhancing R&D efficiency in innovative drugs and complex formulations, particularly in gastrointestinal, mental health, reproductive assistance, and oncology fields[13] - The company has initiated multiple clinical trials, including a Phase III trial for recombinant human IL-17A/F monoclonal antibody injection and completed enrollment for semaglutide injection for type 2 diabetes[10] - The company is focusing on R&D in high-barrier complex formulations and innovative drugs, particularly in reproductive health and oncology[41] - The company is actively pursuing non-equity investments, with a focus on securities investments valued at RMB 198,586,942.57[128] - The company is committed to increasing its R&D investment to improve innovation capabilities and adapt to industry policy changes[182] - The company emphasizes the importance of addressing unmet clinical needs and will continue to invest in innovative research and development of high-value innovative drugs and complex formulations[186] Product Development and Approvals - In 2023, 40 innovative drugs were approved for listing in China, maintaining a stable number of new drug approvals[7] - New products approved in 2023 include Triptorelin Acetate Microspheres and a new indication for Apremilast, enhancing the company's competitive position in various therapeutic areas[9] - The company received emergency use approval for a bivalent COVID-19 vaccine in December 2023, improving accessibility for patients[9] - The company has successfully launched several new products, including tocilizumab injection and new indications for injectable esomeprazole sodium, which are expected to enhance the product pipeline in their respective therapeutic areas[81] - The company is advancing multiple clinical research projects, including treatments for prostate cancer and gastrointestinal diseases, which are expected to enrich its product pipeline[88] Market Strategy and Expansion - The company aims to accelerate the internationalization of its products to ensure sustainable long-term development[9] - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by 2025[27] - The company has introduced innovative drugs in the gastrointestinal and cardiovascular fields, enhancing its international collaboration and licensing efforts[11] - The company is focusing on expanding its product offerings in the mental health sector with the development of Paliperidone injection for schizophrenia, currently in BE testing[85] - The company is exploring international markets and partnerships for innovative drug development to support its globalization strategy[186] Sustainability and ESG - The company’s MSCI ESG rating reached the highest level of AAA, making it the first Chinese pharmaceutical company to achieve this rating[12] - The company aims to achieve carbon neutrality by 2055, emphasizing its commitment to sustainable development and environmental responsibility[14] - The company is committed to strict compliance with environmental regulations, which may increase operational costs but is essential for sustainable practices[189] Financial Management and Investments - The company has invested 150 million RMB in new technology development, focusing on advanced manufacturing processes[27] - The company has completed 167 registration projects for raw materials and intermediates in 103 overseas countries/regions, with 27 international certification certificates obtained[56] - The company has reported a significant asset impairment of ¥310,038,083.02, accounting for -13.01% of total profit, primarily due to inventory write-downs[92] - The company has capital commitments totaling RMB 709.93 million as of December 31, 2023, significantly up from RMB 406.79 million at the end of 2022[116] - The company has made significant equity investments totaling RMB 702,000,000, with a projected loss of RMB -11,178,981.98 for the current period[126] Investor Relations - The company engaged in multiple investor communications throughout 2023, including discussions with institutions like 博裕资本 and IronBirch Capital regarding operational conditions and future development directions[191][192] - The company maintained transparency by not providing any written materials during these discussions, ensuring that all information shared was accurate and factual[191][192] - The company’s investor relations activities were consistently documented and made available on the 巨潮 website for public access[191][192] Operational Efficiency - The company is committed to enhancing its internal operations management and improving supply chain efficiency through smart manufacturing and automation[176] - The company has established a comprehensive quality management system, ensuring the safety and stability of its products[65] - The company is enhancing its quality management system and production processes, leading to improved operational capabilities and cost control[52]

Financial Performance - The company's operating revenue for Q1 2024 was CNY 3,242,814,513.73, a decrease of 4.99% compared to CNY 3,413,055,191.98 in the same period last year[6] - Net profit attributable to shareholders for Q1 2024 was CNY 607,823,809.46, representing an increase of 4.45% from CNY 581,909,331.89 year-on-year[6] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.65, up 4.84% from CNY 0.62 in the same quarter last year[6] - The company reported a gross profit margin of approximately 64.7%, compared to 63.1% in the previous period, indicating an improvement in profitability[38] - The total comprehensive income for the current period is RMB 693,127,170.79, an increase from RMB 547,848,808.47 in the previous period[39] Cash Flow - The net cash flow from operating activities surged by 208.30% to CNY 924,248,920.31, compared to CNY 299,784,593.85 in the previous year[6] - Cash flow from operating activities increased by 208.30% to RMB 924.25 million, attributed to reduced procurement and expense outflows[22] - Operating cash flow for the current period is RMB 924,248,920.31, a significant increase from RMB 299,784,593.85 in the previous period, reflecting a growth of approximately 208.5%[41] - Total cash inflow from operating activities is RMB 3,508,763,815.99, compared to RMB 3,446,124,787.42 in the prior period, indicating a slight increase of about 1.8%[41] - The net increase in cash and cash equivalents for the current period is -RMB 188,391,565.87, compared to an increase of RMB 527,826,015.13 in the previous period[43] Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 25,189,695,757.11, reflecting a slight increase of 0.58% from CNY 25,044,827,127.75 at the end of the previous year[8] - The total liabilities decreased to RMB 9,750,195,000.46 from RMB 10,278,124,131.71, reflecting a reduction of approximately 5.12%[37] - The company's total equity increased to RMB 15,439,500,756.65 from RMB 14,766,702,996.04, representing a growth of about 4.54%[37] - The company's cash and cash equivalents stood at RMB 11,143,148,609.60, down from RMB 11,325,723,855.76 at the beginning of the year[35] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 43,751, with 43,538 being A-share shareholders[25] - The largest shareholder, Hong Kong Central Clearing Limited, holds 33.41% of shares, totaling 309,547,589 shares[25] - The company has initiated a share buyback program, resulting in treasury shares amounting to CNY 128,431,667.85[17] - The company repurchased a total of 2,152,600 A-shares, accounting for 0.23% of the total share capital, with a total expenditure of RMB 73,436,534.00[30] - The company also repurchased 2,476,300 H-shares, representing 0.27% of the total share capital, with a total expenditure of HKD 60,363,260.00[31] Investment and Income - Investment income decreased by 58.41% to RMB 15.72 million, primarily due to last year's dividend income[22] - The company reported a 238.80% increase in minority shareholders' profit to RMB 108.26 million, driven by improved performance of non-wholly owned subsidiaries[22] - Other comprehensive income improved by 65.23%, primarily due to changes in the fair value of other equity instruments and foreign exchange fluctuations[22] Research and Development - Research and development expenses for the current period were RMB 238,173,559.46, down 23.5% from RMB 311,408,248.52 in the previous period[38] Other Financial Metrics - Non-recurring gains and losses for the period totaled CNY 17,522,920.17, primarily driven by government subsidies and asset disposals[13] - Other receivables increased by 43.55% to CNY 45,948,492.93, mainly due to an increase in export tax refunds[17] - The company reported a significant increase of 203.07% in other current assets, totaling CNY 156,230,044.47, attributed to new cash management operations[17] - The company's short-term borrowings decreased to RMB 1,360,009,625.00 from RMB 1,860,009,625.00, a reduction of 27%[37] - The deferred income tax liabilities decreased to RMB 202,497,603.77 from RMB 209,812,292.82, a decline of about 3.5%[37] Audit Status - The company has not undergone an audit for the first quarter report[45]

Financial Performance - The company's revenue for Q1 2024 was RMB 3,242.81 million, a decrease of 4.99% compared to RMB 3,413.06 million in the same period last year[4] - Net profit attributable to shareholders was RMB 607.82 million, an increase of 4.45% from RMB 581.91 million year-on-year[4] - Basic and diluted earnings per share were both RMB 0.65, reflecting a growth of 4.84% from RMB 0.62 in the same quarter last year[4] - The total comprehensive income for the period was RMB 693,127,170.79, compared to RMB 547,848,808.47 in the previous year, indicating a growth of 26.5%[25] - The investment income decreased by 58.41% to RMB 15.72 million, down from RMB 37.80 million in the previous year, primarily due to last year's dividend income[12] Cash Flow - The net cash flow from operating activities surged by 208.30%, reaching RMB 924.25 million compared to RMB 299.78 million in the previous year[4] - The net cash flow from operating activities increased significantly to ¥924,248,920.31, compared to ¥299,784,593.85 in the previous period, marking a growth of approximately 208%[27] - Cash inflow from operating activities totaled ¥3,508,763,815.99, up from ¥3,446,124,787.42, indicating a slight increase of about 1.8%[27] - Cash outflow from operating activities decreased to ¥2,584,514,895.68 from ¥3,146,340,193.57, representing a reduction of approximately 17.9%[27] - The net cash flow from investing activities was negative at -¥457,336,601.18, worsening from -¥64,826,182.09 in the previous period[27] - The net cash flow from financing activities showed a net outflow of RMB 654.61 million, a decrease of 306.71% compared to a net inflow of RMB 316.69 million in the previous year, due to reduced new borrowings and increased loan repayments[14] Assets and Liabilities - Total assets at the end of the reporting period were RMB 25,189.70 million, a slight increase of 0.58% from RMB 25,044.83 million at the end of the previous year[5] - The total liabilities decreased to RMB 9,750,195,000.46 from RMB 10,278,124,131.71, reflecting a reduction of approximately 5.12%[24] - The total current assets as of March 31, 2024, amounted to RMB 17,178,219,962.61, a slight decrease from RMB 17,266,174,718.28 at the beginning of the year[23] - The total non-current assets increased to RMB 8,011,475,794.50 from RMB 7,778,652,409.47 at the beginning of the year[23] Shareholder Information - Shareholders' equity attributable to the parent company increased by 4.01% to RMB 14,606.16 million from RMB 14,042.50 million[5] - The total number of ordinary shareholders at the end of the reporting period was 43,751, with the top ten shareholders holding 33.41% of the shares[15] - As of March 31, 2024, the company repurchased a total of 2,152,600 A-shares, accounting for 0.23% of the total share capital, with a total expenditure of RMB 73,436,534.00[18] - The company also repurchased 2,476,300 H-shares, representing 0.27% of the total share capital, with a total expenditure of HKD 60,363,260.00[19] Operational Highlights - The company plans to continue expanding its market presence and investing in new product development to drive future growth[3] - The company reported a significant increase in minority shareholders' profit, which rose by 238.80% to RMB 108.26 million from RMB 31.95 million in the previous year[12] - The revenue from gastrointestinal products decreased by 25.68% to RMB 588.96 million, while revenue from hormone products increased by 39.89% to RMB 806.93 million[12] - The company experienced a 60.26% increase in revenue from diagnostic reagents and equipment, reaching RMB 235.58 million compared to the previous year[12] Expenses - Research and development expenses for the quarter were RMB 238,173,559.46, down 23.5% from RMB 311,408,248.52 in the previous year[25] - The company reported a decrease in sales expenses to RMB 876,113,247.33 from RMB 964,906,980.93, a decline of 9.2%[25] - The company reported a 522.72% increase in financial expenses, primarily due to increased interest income from deposits[12] Stock Options - The company has a total of 1,001 incentive participants eligible to exercise 7,045,000 stock options at an exercise price of RMB 31.31 per A-share[20] - As of March 31, 2024, 270.66 thousand stock options have been exercised by the incentive participants[21] Buyback Information - The highest purchase price for A-shares during the buyback was RMB 35.15 per share, while the lowest was RMB 32.95 per share[18] - The highest purchase price for H-shares during the buyback was HKD 25.15 per share, with a lowest price of HKD 23.05 per share[19] Cash and Cash Equivalents - The company's cash and cash equivalents stood at RMB 11,143,148,609.60, a decrease from RMB 11,325,723,855.76 at the beginning of the year[23] - The ending cash and cash equivalents balance was ¥10,787,974,836.57, slightly down from ¥10,600,468,696.85[27] Audit Information - The company did not undergo an audit for the first quarter report[28]